KORU Medical Systems, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; comparative figures are for FY 2021. This filing reports annual results, not standalone fourth-quarter results.
Business context
KORU develops and sells portable infusion devices and related tubing and needle sets, primarily for subcutaneous immunoglobulin therapies. Revenue comes from U.S. core sales, international core sales, and novel-therapy products and engineering services. The company operates as one segment.
Financial performance
| Metric | FY 2022 | FY 2021 | Change |
|---|---|---|---|
| Net revenue | $27.90 million | $23.49 million | +18.8% |
| Gross profit / margin | $15.37 million / 55.1% | $13.77 million / 58.6% | Profit +11.6%; margin down 3.5 percentage points |
| Operating expenses | $26.15 million | $20.80 million | +25.7% |
| Operating loss | $10.78 million | $7.03 million | Loss increased |
| Net loss | $8.66 million | $4.56 million | Loss increased 89.8% |
| Net loss per share | $0.19 | $0.10 | Loss per share increased |
| Cash used in operations | $5.40 million | $4.32 million | Cash use increased |
| Cash used in investing | $2.80 million | $0.37 million | Primarily facility and equipment investment |
Domestic core revenue rose 11.3% to $21.21 million; international core rose 8.0% to $4.16 million; novel therapies increased 329.8% to $2.53 million, largely from engineering services and clinical-trial product sales. Gross-margin pressure reflected higher labor and material costs, manufacturing rework and scrap during the transition, product mix, and the greater share of lower-margin NRE services; higher average selling prices partly offset these factors. SG&A increased 15.4%, and R&D doubled to $4.96 million.
Liquidity, debt and balance sheet
- Cash and cash equivalents were $17.41 million at year-end, down from $25.33 million. Current assets were $29.80 million and current liabilities $6.96 million.
- Total assets were $42.33 million; total liabilities were $11.01 million; stockholders’ equity was $31.33 million.
- Operating and investing cash outflows together were $8.21 million. Capital expenditures were approximately $2.76 million, principally for the Mahwah facility and equipment.
- The $3.5 million KeyBank revolving credit facility had no balance outstanding at year-end and was extended to June 1, 2023. The company also reported a $0.43 million current note payable related to insurance-premium financing. Finance-lease liabilities totaled $0.49 million; operating-lease liabilities totaled $4.00 million.
- Management stated cash, operating cash flows and available financing were expected to meet requirements through at least December 31, 2023 / the next 12 months. Longer-term plans may require additional debt or equity financing.
Material changes, outlook and risks
- Manufacturing and office operations were moving from Chester, New York, to a newly leased Mahwah, New Jersey facility. Management expected the manufacturing move to be completed in Q1 2023. The transition of substantially all needle-set and tubing manufacturing to Command Medical Products was expected by Q2 2023.
- Management planned further R&D investment over the next 12 months, including development capability for a next-generation infusion pump and consumable system. No quantified revenue or earnings guidance was provided.
- Management cited growth in SCIg prescriptions and market opportunities in additional subcutaneous therapies as strategic drivers. Execution depends on product development, regulatory clearance, clinical and commercial adoption, and biopharmaceutical partners’ programs.
- Key disclosed risks include manufacturing-transition disruption, reliance on single-source suppliers, and distributor/customer concentration: five distributors represented about 72% of net revenue, one U.S. distributor about 41%, and three major distributor customers about 64% of net product revenue.
- EU MDR compliance will require investment; the filing says current Class IIa products may continue to be sold under existing certificates through December 2028 or certificate expiry, whichever comes first, subject to conditions. Failure to meet requirements could prevent EU sales. UKCA requirements also affect continued Great Britain sales after July 1, 2024.
- Other risks include drug and plasma supply, reimbursement and pricing pressure, competition and technological change, inflation, foreign exchange, international operations, and access to future capital. The company noted civil unrest in Nicaragua, where most products are assembled and packaged.
- FY 2022 net loss included a $2.01 million income-tax benefit. The company reported a $0.7 million Employee Retention Credit receivable at year-end 2021 and stated it had not been received by year-end 2022.
- No material legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective. The auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether the Mahwah move and Command manufacturing transition were completed on schedule, without supply interruptions or further margin costs.
- Whether revenue growth—especially novel-therapy revenue—continues and converts into improved gross margin and reduced operating losses.
- Cash burn, capital needs, and the status and terms of credit availability after the June 2023 revolver maturity date.
- Distributor concentration and any changes in customer purchasing patterns or dependence on immunoglobulin/plasma supply.
- Progress, costs and deadlines for EU MDR and UKCA compliance, and receipt of the outstanding Employee Retention Credit.